BaroFold Inc. Initiates First Human Studies For Multiple Sclerosis Drug Candidate, BaroFeron?

BaroFold Inc. announced that it has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of BaroFeron? (IFNβ-1b). In published preclinical studies BaroFeron demonstrated enhanced pharmacological properties, both pharmacokinetics and pharmacodynamics, when compared to commercial interferon beta products.

More: continued here

Filed under: Clinical Trials on June 19th, 2008